4ª PONENCIA - Alergología e Inmunología Clínica - Sociedad ...

30. Tanaka H, Nagai H, Maeda Y. Effect of anti-IL-4 and anti-IL-5
antibodies on allergic airway hyperresponsiveness in mice. Life Sci
1998; 62: L169-174.
31. Karras JG, McGraw K, McKay RA, Cooper SR, Lerner D, Lu T, et
al. Inhibition of antigen-induced eosinophilia and late phase airway
hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse
models of asthma. J Immunol 2000; 164: 5409-5415.
32. Leckie MJ, ten Brinke A, Khan J, Diamant Z, o´Connor BJ,
Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody
on eosinophils, airway hyper-responsiveness, and the late asthmatic
response. Lancet 2000; 356: 2144-2148.
33. England BP, Balasubramanian P, Uings I, Bethell S, Chen MJ,
Schatz PJ, et al. A potent dimeric peptide antagonist of interleukin-5
that binds two interleukin-5 receptor alpha chains. Proc Natl Acad
Sci U S A 2000; 97: 6862-6867.
34. Brusselle GG, Kips JC, Tavernier JH, Van der Heyden JG, Cuvelier
CA, Pauwels RA, et al. Attenuation of allergic airway inflammation
in IL-4 deficient mice. Clin Exp Allergy 1994; 24: 73-80.
35. Coyle AJ, Le Gros G, Bertrand C, Tsuyukis, Heusser CH, Kopf H,
et al. Interleukin-4 is required for the induction of lung Th2 mucosal
immunity. Am J Respir Cell Mol Biol 1995; 13: 54-59.
36. Henderson WR, Jr., Chi EY, Maliszewski CR. Soluble IL-4 receptor
inhibits airway inflammation following allergen challenge in a
mouse model of asthma. J Immunol 2000; 164: 1086-1095.
37. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB,
Agosti JM, et al. Interleukin-4 receptor in moderate atopic asthma. A
phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care
Med 1999; 160: 1816-1823.
38. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore
JB, et al. Efficacy of soluble IL-4 receptor for the treatment of
adults with asthma. J Allergy Clin Immunol 2001; 107: 963-970.
39. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin
Immunol 2001; 107: 9-18.
40. Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG,
Licntenstein LM, et al. IL-13 expression at the sites of allergen challenge
in patients with asthma. J Immunol 1995; 155: 2688-2694.
41. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martín RJ,
et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation
in response to steroid therapy. Am J Respir Crit Care Med
1997; 155: 845-851.
42. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Plister,
et al. Elevated expression of messenger ribonucleic acid encoding IL-
13 in the bronchial mucosa of atopic and nonatopic subjects with
asthma. J Allergy Clin Immunol 1997; 99: 657-665.
43. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F,
Rennick DM, et al. Requirement for IL-13 independently of IL-4 in
experimental asthma. Science 1998; 282: 2261-2263.
44. Oshima Y, Puri RK. Characterization of a powerful high affinity
antagonist that inhibits biological activities of human interleukin-13.
J Biol Chem 2001; 276: 15185-15191.
45. Shimbara A, Christodoulopoulus P, Soussi-Gounni A, Olivenstein
R, Nakamuru Y, Levitt RC, et al. IL-9 and its receptor in allergic and
nonallergic lung disease: increased expresión in asthma. J Allergy
Clin Immunol 2000; 105: 108-115.
46. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti
TNF alpha therapy is useful in rheumatoid artritis and Crohn disease:
análisis of the mechanism of action predicts utility in other diseases.
Transplant Proc 1998; 30: 4126-4127.
Avances en farmacoterapia antialérgica
47. Bertrand CP, Ponath PD. CCR3 blockade as a new therapy for
asthma. Expert Opin Investig Drugs 2000; 9: 43-52.
48. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham
PR, et al. A small molecule antagonist of chemokine receptors
CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3mediated
HIV-1 entry. J Biol Chem 2000; 275: 25985-25992.
49. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, et al. Chemokine
receptor usage by human eosinophils. The importance of
CCR3 demonstrated using an antagonistic monoclonal antibody. J
Clin Invest 1997; 99: 178-184.
50. Abbas A, Williams M, Burnstein H. Activation and functions of
CD4+ T-cell subsets. Immunol Rev 1991; 123: 5-22.
51. Sousa A, Trigg C, Lane S. Effect of inhaled glucocorticosteroids
on IL-1 beta and IL-1 receptor antagonist (IL-1ra) expression in asthmatic
bronchial epithelium. Thorax 1997; 52: 407-410.
52. Borish L, Aarons A, Rumbyrt J. Interleukin-10 regulation in normal
subjects and patients with asthma. J Allergy Clin Immunol
1996; 97: 1288-1296.
53. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH,
Rask-Madsen J, et al. Interleukin 10 (Tenovil) in the prevention of
postoperative recurrence of Crohn's disease. Gut 2001; 49: S2-46.
54. Barnes PJ. Cytokine-directed therapies for asthma. J Allergy Clin
Immunol 2001; 108 (2 Suppl): S72-76.
55. Pauwels RA, Brusselle GJ, Kips JC. Cytokine manipulation in
animal models of asthma. Am J Respir Crit Care Med 1997; 156 (4
Pt 2): S78-81.
56. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental
commitment to the Th2 lineage by extinction of IL-12
signaling. Immunity 1995; 2: 665-675.
57. Bentley A, Hamid Q, Robinson D. Prednisolone treatment in
asthma. Reductions in the numbers of eosinophils, T cells, tryptaseonly
positive mast cells, and modulation of IL-4, IL-5 and interferon
gamma cytokine gen expression within the bronchial mucosa. Am J
Respir Crit Care Med 1996; 153: 551-556.
58. Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J,
et al. Effects of recombinant human interleukin-12 on eosinophils,
airway hyper-responsiveness, and the late asthmatic response. Lancet
2000; 356: 2149-2153.
59. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu
DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin
plus free recombinant IL-12 in inducing a T helper cell type 1dominated
immune response and inhibiting antigen-specific IgE production.
J Immunol 1997; 158: 4137-4144.
60. Shimoda K, Deursen J, Sangster MY, Sarawar SR, Carson RT,
Tripp RA. Lack of IL-4-induced Th2 response and IgE class switching
in mice with disrupted Stat 6 gene. Nature 1996; 380: 630-632.
61. Hamid QA, Minshall EM. Molecular pathology of allergic disease.
Lower airway disease. J Allergy Clin Immunol 2000; 105: 20-36.
62. Nakamura Y, Ghaffar O, Olivenstein R, Taha RA, Soussi-Gounni
A, Zhang DH, et al. Gene expression of the GATA-3 transcription factor
is increased in atopic asthma. J Allergy Clin Immunol 1999; 103
(2 Pt 1): 215-222.
63. Bertrand CP. Asthma: where beyond steroids? Curr Opin Chem
Biol 2000; 4: 407-411.
64. Pretolani M, Ruffie C, Lapa E, Joseph D, Lobb RR, Vargafting
BB. Antibody to very late activation antigen 4 prevents antigen-induced
bronchial hyperreactivity and cellular infiltration in the guinea pig
airways. J Exp Med 1994; 180: 795-805.
141